Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in August

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 313,000 shares, a decrease of 7.0% from the August 15th total of 336,500 shares. Based on an average daily trading volume, of 63,900 shares, the days-to-cover ratio is currently 4.9 days. Approximately 1.3% of the company’s stock are short sold.

Insider Activity

In other news, Director Nassim Usman sold 3,452 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $12.00, for a total transaction of $41,424.00. Following the completion of the transaction, the director now directly owns 1,636 shares in the company, valued at approximately $19,632. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.92% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GYRE. Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at $166,000. WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at $220,000. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at $123,000. Finally, Bank of New York Mellon Corp purchased a new stake in Gyre Therapeutics in the 2nd quarter worth about $218,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Stock Down 0.1 %

Shares of NASDAQ GYRE opened at $14.04 on Wednesday. Gyre Therapeutics has a 1-year low of $4.80 and a 1-year high of $30.40. The business’s fifty day moving average price is $12.91 and its two-hundred day moving average price is $13.95.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $25.23 million for the quarter. As a group, equities research analysts anticipate that Gyre Therapeutics will post -0.45 EPS for the current fiscal year.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.